Stock RACA THES ACQU
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News THES ACQU

Equities

RACA

US88339T1034

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
POINT BIOPHARMA GLOBAL INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Financial Statements and Exhibits (form 8-K)
AQ
THERAPEUTICS ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
AQ
Therapeutics Acquisition Corp.(NasdaqCM:RACA) dropped from NASDAQ Composite Index
CI
Point Biopharma Inc. completed the acquisition of Therapeutics Acquisition Corp. from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction.
CI
THERAPEUTICS ACQUISITION CORP. : Other Events (form 8-K)
AQ
Therapeutics Acquisition : Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT. Special Meeting Scheduled for June 29, 2021 (Form 8-K)
PU
THERAPEUTICS ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Therapeutics Acquisition : Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
BU
Therapeutics Acquisition : POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC (Form 8-K)
PU
THERAPEUTICS ACQUISITION CORP. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
CI
Therapeutics Acquisition : Point Biopharma Phase 3 Trial for Cancer Therapy Doses First Patient Group
MT
Therapeutics Acquisition : Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manufacturing facility (Form 8-K)
PU
THERAPEUTICS ACQUISITION CORP. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Therapeutics Acquisition : POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
BU
THERAPEUTICS ACQUISITION : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Therapeutics Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Therapeutics Acquisition : Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manufacturing facility
PU
THERAPEUTICS ACQUISITION CORP. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Merck : Completes Pandion Therapeutics Acquisition
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RACA Stock
  4. News THES ACQU